ライフサイエンスコーパス: incontinence

1 ce regarding the efficacy of PTNS in urinary incontinence.

2 dification can lessen urgency, nocturia, and incontinence.

3 ogic surgery, urinary retention, and urinary incontinence.

4 fashion which minimizes the risk of urinary incontinence.

5 No patient developed fecal incontinence.

6 s for treating patients with refractory urge incontinence.

7 ositive effect in men with postprostatectomy incontinence.

8 management of defecatory disorders and fecal incontinence.

9 treatment of the components of mixed urinary incontinence.

10 ssessment of men with urinary urgency and/or incontinence.

11 about the long-term outcome of SNS for fecal incontinence.

12 peutic options for women affected by urinary incontinence.

13 l-sling surgery in women with stress urinary incontinence.

14 r group developed ischemic colitis and fecal incontinence.

15 dication or indwelling catheters for urinary incontinence.

16 re < 3), and 6 patients (8.5%) had recurrent incontinence.

17 ing nerve damage to create models of urinary incontinence.

18 olapse are at risk for postoperative urinary incontinence.

19 equency of daily episodes of urgency urinary incontinence.

20 onths, allowing for subsequent treatment for incontinence.

21 lic events, gallbladder disease, and urinary incontinence.

22 s of preventing postoperative stress urinary incontinence.

23 -to-one pelvic floor muscle training reduces incontinence.

24 ng 381 women with refractory urgency urinary incontinence.

25 lling refractory episodes of urgency urinary incontinence.

26 d to new treatments for diseases like faecal incontinence.

27 this tone leads to disorders such as faecal incontinence.

28 ad the skills to manage patients with faecal incontinence.

29 PTNS) is a new ambulatory therapy for faecal incontinence.

30 ary frequency, urgency, and at times urinary incontinence.

31 ation in the treatment of adults with faecal incontinence.

32 electrical stimulation in adults with faecal incontinence.

33 incter muscle as a method for treating fecal incontinence.

34 phenotypes in defecatory disorders and fecal incontinence.

35 ever, this is associated with a high rate of incontinence.

36 sing men with the symptoms of urgency and/or incontinence.

37 Some patients reported symptoms of fecal incontinence.

38 onths after treatment, 2 developed recurrent incontinence 1 year after treatment, 1 developed recurre

39 Acquired deformities (13%), incontinence (11%), non-injury wounds (9%), and pelvic o

40 1 more cases [95% CI, 3 to 22]), and urinary incontinence (1261 more cases [95% CI, 880 to 1689]).

41 33 more per 10 000 woman-years), and urinary incontinence (1271 more per 10 000 woman-years).

42 al atrophy (P = .01), nonobstructive urinary incontinence (18.5% vs 3.9%; P = .04), and syncope (37%

43 year after treatment, 1 developed recurrent incontinence 2 years after treatment, and 1 developed in

44 el movements/week and </= 1 episode of fecal incontinence/2 weeks, from study weeks 5-8 (responders).

45 The most commonly investigated was faecal incontinence (32 studies, 91%).

46 nce 2 years after treatment, and 1 developed incontinence 5 years after treatment.

47 12 points for sexual function, 6 for urinary incontinence, 5 for urinary irritative symptoms, 5 for b

48 Among these patients, 2 developed recurrent incontinence 6 months after treatment, 2 developed recur

49 in the placebo group had a history of fecal incontinence; 60.4% and 55.1% in the prucalopride and pl

50 22 more per 10 000 woman-years), and urinary incontinence (872 more per 10 000 woman-years).

51 ke (9 more cases [95% CI, 2 to 19]), urinary incontinence (876 more cases [95% CI, 606 to 1168]), and

52 Mixed urinary incontinence, a condition of both stress and urge urinar

53 95% CI, 1.08 to 1.52; P = .005), and urinary incontinence (adjusted OR, 1.42; 95% CI, 1.20 to 1.69; P

54 activity are the major categories of urinary incontinence affecting men.

55 Male urinary incontinence affects a significant number of elderly men

56 The high rates of persisting incontinence after 12 months suggest a substantial unrec

57 Stress urinary incontinence after prostate cancer treatment is common.

58 Urinary incontinence after treatment for prostate cancer is comm

59 CI 0.49-1.79]); an increased risk of further incontinence (aIRR 3.20 [2.06-4.96]) and prolapse surger

60 At 12 months, urinary incontinence (allowing for subsequent treatment of incon

61 sults support the use of mesh procedures for incontinence, although further research on longer term o

62 sults support the use of mesh procedures for incontinence, although further research on longer term o

63 ted with better resident outcomes of urinary incontinence among organizational factors.

64 gnosis in primary care of urinary and faecal incontinence among people aged 60-89 with dementia, and

65 consequences of the surgery such as urinary incontinence, anastomotic contracture, erectile dysfunct

66 e preoperative incidence (11.1% vs 37.5% for incontinence and 15.6% vs 54.0% for constipation).

67 0-17); 28% of patients had never experienced incontinence and 60% had fragmentation.

68 Stress urinary incontinence, overflow incontinence and detrusor overactivity are the major cat

69 The management of children with urinary incontinence and dysfunctional voiding problems can be v

70 Urinary incontinence and erectile and sexual dysfunction were ea

71 trouble; prostate cancer was associated with incontinence and falls; cervical/uterine cancer was asso

72 aires, were participants' reports of urinary incontinence and incremental cost per quality-adjusted l

73 Both rates of fecal incontinence and obstructed defecation decreased signifi

74 conservative management in men with urinary incontinence and other LUTS.

75 ntegrin signaling from urothelium results in incontinence and overactive bladder due to abnormal mech

76 out the safety of surgery for stress urinary incontinence and pelvic organ prolapse using transvagina

77 use of vaginal mesh for both stress urinary incontinence and POP.

78 hs after surgery, he had mild stress urinary incontinence and PSA of < 0.1 ng/mL.

79 Heavy incontinence and radiation history are strongly associat

80 due to the occurrence of postoperative anal incontinence and the high rate of recurrence.

81 l involving women without symptoms of stress incontinence and with anterior prolapse (of stage 2 or h

82 rned about the potential for greater urinary incontinence and/or urinary irritation associated with t

83 outcome domains (including fecal urgency and incontinence), and three oncological outcome domains (in

84 tion and irritation, 9.7 to 10.5 for urinary incontinence, and 5.7 to 6.1 for bowel problems.

85 ies, megacolon/megarectum, degree of soiling/incontinence, and anorectal manometry profile(s).

86 urinary obstruction and irritation, urinary incontinence, and bowel problems-each scored from 0 (no

87 swallowing difficulties, tinnitus, and fecal incontinence, and he had undergone cataract surgery at t

88 three times the rate of diagnosis of urinary incontinence, and more than four times the rate of faeca

89 balance difficulties with falls and urinary incontinence, and one was wheelchair bound.

90 tion of fistula recurrence, residual urinary incontinence, and pregnancy after successful fistula clo

91 ted with lower rates of hemorrhage, maternal incontinence, and rare but serious neonatal outcomes.

92 sociodemographics, cognitive status, urinary incontinence, and self-reported ability to do activities

93 iculitis, enhanced recovery protocols, fecal incontinence, and single incision laparoscopic surgery.

94 disease process in overactive bladder, urge incontinence, and spinal cord injury.

95 ch, frequency of defecation and incidence of incontinence, and the patients' perception of QOL.

96 increased rates of low BMI, injurious falls, incontinence, and vision loss.

97 to claims indicative of urethritis, urinary incontinence, and/or obstruction.

98 ive modes of electrical stimulation for urge incontinence are also briefly reviewed.

99 tance: Women with refractory urgency urinary incontinence are treated with sacral neuromodulation and

100 y tract symptoms (LUTS), such as urgency and incontinence, are common, especially among the elderly,

101 timulation in the treatment of men with urge incontinence, as well as evaluates the financial implica

102 r nerve damage, such as urinary retention or incontinence, as well as for the development of strategi

103 ial 2, the difference in the rate of urinary incontinence at 12 months (126 [65%] of 194) from the co

104 with a sling to prevent one case of urinary incontinence at 12 months was 6.3.

105 second primary end point was the presence of incontinence at 12 months, allowing for subsequent treat

106 surgery resulted in a lower rate of urinary incontinence at 3 and 12 months but higher rates of adve

107 of sacral nerve stimulation (SNS) for fecal incontinence at 5 years after implantation and to identi

108 Prevention of postoperative stress urinary incontinence at the time of prolapse repair is controver

109 Thus, it is important that urinary incontinence be amenable to improving conditions with ap

110 in men compared with women, despite urinary incontinence being relatively common and burdensome in m

111 =65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures,

112 have complete resolution of urgency urinary incontinence but had higher rates of transient urinary r

113 inumtoxinA are used to treat urgency urinary incontinence, but data directly comparing the two types

114 ts only modest relief of male stress urinary incontinence, but may be recommended in some patients.

115 may benefit a subset of patients with fecal incontinence, but more controlled studies are needed.

116 d in women before surgery for stress urinary incontinence, but there is no good evidence that they im

117 ith weight loss, for treating stress urinary incontinence by performing anti-incontinence procedures

118 ntified, and studies have shown that urinary incontinence can have substantial negative impacts on va

119 rganizational factors that influence urinary incontinence care quality controlling for patient level

120 impact of organizational factors on urinary incontinence care quality defined as the improvement of

121 e (p=0.014), dysphagia (p=0.003) and urinary incontinence/catheterisation (p=0.000) were at higher ri

122 able as judged by the clinical team and with incontinence classified as stress, urge, mixed or 'funct

123 macological treatment of male stress urinary incontinence, confirming that duloxetine had a modest po

124 Surgical therapies for fecal incontinence continue to evolve and show promise in impr

125 Clinicians should prioritize urinary incontinence detection, identify and treat modifiable fa

126 The Questionnaire for Urinary Incontinence Diagnosis, the Psychological General Well-B

127 nd anal cancers; inflammatory bowel disease; incontinence; diverticulitis; hemorrhoids; fistulas; and

128 nt data on the medical treatment of men with incontinence due to overactive bladder or to stress urin

129 Patient's age, improvement of urge incontinence during PNE, and sustained efficacy during t

130 Percentage reduction in mean number of incontinence episodes after 8 weeks of treatment as docu

131 Mean incontinence episodes decreased from 28 to 13 per week (

132 tive predictors included improvement of urge incontinence episodes during percutaneous nerve evaluati

133 aseline mean number of daily urgency urinary incontinence episodes over 6 months, was measured with m

134 Deferment time and average number of weekly incontinence episodes were also estimated from a prospec

135 egular voiding intervals that reduce urgency incontinence episodes.

136 delayed-treatment control, resulted in fewer incontinence episodes.

137 ded 24 cases of post-repair residual urinary incontinence, equivalent to a cumulative incidence of 23

138 As surgical treatment of stress incontinence evolves, thorough understanding of sling su

139 igher prevalence of hearing trouble, urinary incontinence, falls, depression, and osteoporosis than t

140 evels can contribute to development of fecal incontinence (FI) in women after menopause by altering n

141 Chronic diarrhea with fecal incontinence (FI) is a severe, underreported, and intrac

142 The prevalence of faecal incontinence (FI) varies worldwide, and in Malaysia is n

143 agement of common anorectal disorders: fecal incontinence (FI), functional anorectal pain and functio

144 effective as stimulation at the ST for fecal incontinence (FI).

145 ous tibial nerve stimulation (PTNS) in fecal incontinence (FI).

146 Among patients with postprostatectomy incontinence for at least 1 year, 8 weeks of behavioral

147 The 5 most important items were "incontinence for flatus," "incontinence for liquid stool

148 rtant items were "incontinence for flatus," "incontinence for liquid stools," "frequency," "clusterin

149 ed 18 years or older with substantial faecal incontinence for whom conservative treatments (such as d

150 or pulmonary arterial hypertension, urinary incontinence, gastrointestinal and neuropsychiatric dise

151 man in his 30s with paraparesis and urinary incontinence had a long-segment thoracic lesion on spina

152 Surgical treatment of fecal incontinence has evolved from colostomy and direct repai

153 chniques emerge, treatment of stress urinary incontinence has increased over time.

154 Fecal incontinence (hazard ratio [HR], 1.78; 95% confidence in

155 The odds of urinary incontinence improvement from admission in urban long-te

156 alls in 76%, pyramidal signs in 54%, urinary incontinence in 50% and dementia in 39%.Visual hallucina

157 vents of these procedures for stress urinary incontinence in England over 8 years.

158 Recent research has focused less on urinary incontinence in men compared with women, despite urinary

159 xcellent options for managing stress urinary incontinence in men, and recent data have allowed us to

160 d information on the epidemiology of urinary incontinence in men.

161 Incontinence in people with dementia is distressing, add

162 Successful and safe management of incontinence in people with dementia presents additional

163 The clinical management of urinary incontinence in people with dementia with medication and

164 pragmatically appropriate to manage urinary incontinence in select patients.

165 The rates of first diagnosis for faecal incontinence in the dementia cohort were 11.1 (10.4-11.9

166 t risk (95% confidence interval) for urinary incontinence in the dementia cohort, among men and women

167 and more than four times the rate of faecal incontinence, in UK primary care.

168 Specialist treatments for urgency incontinence include onabotulinumtoxinA and percutaneous

169 examined risk factors and impact of urinary incontinence, including lifestyle, comorbidities and med

170 Risks of tumor spillage and fecal incontinence induced by transanal extraction are not kno

171 For women with stress urinary incontinence, initial midurethral-sling surgery, as comp

172 Initial assessment of men with incontinence involves a focussed history, examination an

173 100 IU) in patients with non-neurogenic urge incontinence is 33 and 5%, respectively.

174 Fecal incontinence is a challenging condition with numerous av

175 Urinary incontinence is a common clinical problem, particularly

176 Fecal incontinence is a significant source of morbidity and de

177 Conservative treatment for urinary incontinence is an effective intervention and has been r

178 Urinary incontinence is an important condition affecting many re

179 Urinary incontinence is common immediately after prostate surger

180 Urinary incontinence is common in women, although few seek care

181 The treatment of male urinary incontinence is constantly evolving, with recent advance

182 ce for treatment of women with mixed urinary incontinence is lacking, as are clear diagnostic criteri

183 Incontinence is not an isolated symptom in men, but rath

184 Male urinary incontinence is often seen following prostate surgery an

185 a condition of both stress and urge urinary incontinence, is prevalent in 20% to 36% of women and is

186 Patients with stress urinary incontinence mainly suffer from malfunction of the ureth

187 Concerning urinary function, the grade of incontinence measured 1 year after the intervention was

188 Urgency incontinence medications, with timely reassessment of sy

189 d as first-line treatment for stress urinary incontinence; midurethral-sling surgery is generally rec

190 stent with the International Consultation on Incontinence modular Questionnaire modules.

191 inal surgery for prolapse and stress urinary incontinence, neither ULS nor SSLF was significantly sup

192 fer new avenues for the treatment of urinary incontinence of central origin.

193 should focus on understanding the effect of incontinence on quality of life, the patient's goals and

194 She denies fecal incontinence or change in stool caliber.

195 ing from increased bowel frequency to faecal incontinence or evacuatory dysfunction.

196 One primary end point was urinary incontinence or treatment for this condition at 3 months

197 At 3 months, the rate of urinary incontinence (or treatment) was 23.6% in the sling group

198 symptomatic orthostatic hypotension, urinary incontinence, or both) at diagnosis (n=62) had a worse p

199 Stress urinary incontinence, overflow incontinence and detrusor overact

200 fter stratification by type and frequency of incontinence, participants were randomized to 1 of 3 gro

201 had five or more episodes of urgency urinary incontinence per 3-day period, as recorded in a diary.

202 baseline in mean episodes of urgency urinary incontinence per day over the 6-month period, as recorde

203 ean reduction in episodes of urgency urinary incontinence per day over the course of 6 months, from a

204 n 6-month mean number of episodes of urgency incontinence per day than did the 174 in the sacral neur

205 eduction in the number of episodes of faecal incontinence per week compared with 32 (31%) of 102 pati

206 % or greater reduction in episodes of faecal incontinence per week.

207 y-dwelling men aged 51 through 84 years with incontinence persisting 1 to 17 years after radical pros

208 andomized trials in women with mixed urinary incontinence populations are needed.

209 er complications including postprostatectomy incontinence (PPI).

210 [8 constipation predominant (group 1) and 5 incontinence predominant (group 2)] had a 3-week trial o

211 h uncomplicated, demonstrable stress urinary incontinence, preoperative office evaluation alone was n

212 20 years or older undergoing a first, single incontinence procedure or prolapse procedure during 1997

213 2016, 16 660 women underwent a first, single incontinence procedure, 13 133 (79%) of which used mesh.

214 cently advocated for the routine use of anti-incontinence procedures at the time of prolapse surgery;

215 Voiding dysfunction after anti-incontinence procedures is not an uncommon finding, alon

216 ress urinary incontinence by performing anti-incontinence procedures of both traditional and mid-uret

217 e to overactive bladder or to stress urinary incontinence published in peer-reviewed journals.

218 of life was assessed with the Rockwood Fecal Incontinence Quality of Life questionnaire.

219 luded complete resolution of urgency urinary incontinence, quality of life, use of catheters, and adv

220 atients were evaluated with the Wexner Fecal Incontinence Questionnaire after stoma closure.

221 viours and the International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Sy

222 ever, there was no significant difference in incontinence reduction between the treatment groups (P =

223 ethral bulking and oral medicines for stress incontinence remains low because of inconsistent results

224 r diagnosis and evaluation of stress urinary incontinence remains paramount in preventing surgical co

225 The Wexner incontinence score dropped from 16.5 +/- 2.5 for pre-SNS

226 The median Wexner fecal incontinence score was 9 (possible range: 0-20), and the

227 95% CI: 1.72-132; P = 0.036), improvement of incontinence scores at 6 months from baseline (OR: 6.29;

228 4.3; P = 0.025), particularly improvement of incontinence scores from 3 to 6 months (OR: 41.5; 95% CI

229 Wexner incontinence scores improved significantly from a baseli

230 Incontinence scores were measured using a validated ques

231 ostate Cancer Index Composite (EPIC) urinary incontinence scores were similar at baseline as and 12 m

232 Fecal incontinence seems to be a problem.

233 ; or overall UI score of 3 or greater on the Incontinence Severity Index.

234 n-group differences in secondary measures of incontinence severity, quality of life, patient satisfac

235 h as overactive bladder syndrome and urinary incontinence significantly increase with age.

236 ate interventions, since a change in urinary incontinence status can reflect care quality in long-ter

237 (0.19) in the RN ratio, the odds of urinary incontinence status improvement or maintenance of contin

238 uality defined as the improvement of urinary incontinence status or maintenance of continent status p

239 There are an increasing number of urinary incontinence studies outside Europe and North America.

240 a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism

241 ngs for the treatment of male stress urinary incontinence (SUI) has increased over the last decade.

242 gan prolapse (POP) repair and stress urinary incontinence (SUI) to augment and strengthen weakened ti

243 Stress urinary incontinence (SUI) with more than 1 symptom or interval

244 ence for the genetic basis of stress urinary incontinence (SUI).

245 surgical treatment for female stress urinary incontinence (SUI).

246 [0.24-0.39]), and a similar risk of further incontinence surgery (0.90 [0.73-1.11]) and later compli

247 in predicting voiding dysfunction after anti-incontinence surgery is reviewed.

248 tine urodynamics in patients undergoing anti-incontinence surgery is somewhat controversial, with mix

249 r later postoperative complications, further incontinence surgery, or further prolapse surgery.

250 Stress incontinence surgery, the midurethral sling, is associat

251 ding dysfunction in patients undergoing anti-incontinence surgery.

252 lower urinary tract symptom, nearly 50% had incontinence symptoms, 40% had filling symptoms, and 18%

253 statectomy was associated with worse urinary incontinence than EBRT (-18.0 points; 95% CI, -20.5 to -

254 ater decrease in sexual function and urinary incontinence than either EBRT or active surveillance aft

255 ostatectomy were more likely to have urinary incontinence than were those undergoing radiotherapy at

256 nificant portion of whom report urge urinary incontinence that is inadequately treated with first-lin

257 neurologic disease) associated with urinary incontinence, the clinician should initiate unsupervised

258 Urinary incontinence, the involuntary loss of urine, is a common

259 High-quality, level 1 evidence for urinary incontinence therapy can guide clinicians in the treatme

260 e have not changed significantly for urinary incontinence, there have been recent advances with minim

261 h uncomplicated, demonstrable stress urinary incontinence to compare outcomes after preoperative offi

262 d with hypervirulent ribotypes or with stool incontinence, to determine the rate of transmission.

263 ing regarding the treatment of mixed urinary incontinence, treatment generally begins with conservati

264 Among women with refractory urgency urinary incontinence, treatment with onabotulinumtoxinA compared

265 Urinary incontinence (UI) affects between 40 and 60% of people i

266 or over with a diagnosis of stroke; urinary incontinence (UI) as defined by the International Contin

267 Urinary incontinence (UI) in women adversely affects quality of

268 ons on the nonsurgical management of urinary incontinence (UI) in women.

269 hough pregnancy is a risk factor for urinary incontinence (UI), the extent of UI in nulligravid women

270 re dysfunctional urination including urinary incontinence (UI).

271 Women without stress urinary incontinence undergoing vaginal surgery for pelvic-organ

272 ir breakdown, urinary retention, or residual incontinence up to 3 months after surgery.

273 bowel dysfunction (LAR syndrome [LARS]) with incontinence, urgency, and frequent bowel movements.

274 ndomised controlled trial (CONtrol of Faecal Incontinence using Distal NeuromodulaTion [CONFIDeNT]) i

275 on issues for these patients include urinary incontinence, vaginal stenosis, clitoral pain, and cosme

276 ation of severe sepsis with injurious falls, incontinence, vision loss, hearing loss, and chronic pai

277 (injurious falls, low body mass index [BMI], incontinence, vision loss, hearing loss, and chronic pai

278 tio for pharmacological treatment of urinary incontinence was 2.2 (1.4-3.7) for both genders, and for

279 ed rate ratio for first diagnosis of urinary incontinence was 3.2 (2.7-3.7) in men and 2.7 (2.3-3.2)

280 n and 2.7 (2.3-3.2) in women, and for faecal incontinence was 6.0 (5.1-7.0) in men and 4.5 (3.8-5.2)

281 e surveillance at 3 months, worsened urinary incontinence was associated with radical prostatectomy (

282 h apical vaginal prolapse and stress urinary incontinence was conducted between 2008 and 2013 at 9 US

283 ween-group difference in the odds of urinary incontinence was noted at 15 years.

284 Complete resolution of urgency urinary incontinence was reported by 13% and 27% of the women, r

285 Incontinence was slightly more common in students than i

286 inence (allowing for subsequent treatment of incontinence) was present in 27.3% and 43.0% of patients

287 Recurrence and incontinence were evaluated during each visit.

288 All 38 men with no baseline urinary incontinence were leak-free and pad-free by 9 months.

289 sis, results, and treatment of mixed urinary incontinence were selected for review.

290 nent patients (16.6%) reported postoperative incontinence (Wexner Score < 3), and 6 patients (8.5%) h

291 the pathophysiology of urinary retention and incontinence where sensory feedback may engage these ref

292 e, pain (spinal and peripheral), and urinary incontinence, whereas NOP antagonists have been investig

293 re surgery, 22 patients (32%) reported fecal incontinence, which improved after surgery in 15 cases (

294 olving women with idiopathic urgency urinary incontinence who had five or more episodes of urgency ur

295 urethropexies, and for managing urge urinary incontinence with anticholinergic medications.

296 lity (level 1) evidence for treating urinary incontinence with weight loss, for treating stress urina

297 A review of the diagnosis of male urinary incontinence, with particular reference to studies publi

298 surgical options for the treatment of fecal incontinence within the context of established therapies

299 299 scenarios, including urinary retention, incontinence, wounds, urine volume measurement, urine sa

300 women residing in nursing homes have urinary incontinence, yet only 25% seek or receive treatment.